Deutsche Bank Reiterates Buy Rating for DexCom, Inc. with $86 Target
Deutsche Bank reaffirms its buy rating for DexCom, Inc., setting a target price of $86, a 23.30% upside from the current price.
Key Points
- Deutsche Bank reiterated its buy rating for DexCom, Inc. (DXCM) on June 23, 2026, with a target price of $86.
- Deutsche Bank's $86 price target implies 23.30% upside from DexCom, Inc.'s ($DXCM) current $69.75 share price.
- Shares of DXCM traded near $69.07 on Tuesday, and the company has a market cap of $26.65 billion with a P/E ratio of 29.6.
- Insider transactions in June included planned sales by executives and open market buys by directors.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Deutsche Bank has reaffirmed its buy rating for DexCom, Inc. (NasdaqGS: DXCM) with a target price of $86. Analyst Kieran Ryan reiterated the rating on June 23, 2026. Shares of DexCom traded near $69.07 on Tuesday.
Deutsche Bank vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in DexCom, Inc.
Several institutional investors have recently adjusted their holdings in DexCom. BlackRock, Inc. reduced its stake by 884,006 shares, leaving it with 38,964,371 shares worth about $2.45 billion, a 2.2% decrease. Vanguard Capital Management LLC opened a new position with 25,020,961 shares valued at approximately $1.57 billion. Similarly, Vanguard Portfolio Management LLC also initiated a new holding with 19,219,953 shares, valued at around $1.21 billion. State Street Corp trimmed its holdings by 158,707 shares, bringing its total to 17,934,847 shares worth about $1.13 billion, a 0.9% decrease. Meanwhile, Baillie Gifford & Co slightly increased its stake by 46,938 shares, totaling 15,599,525 shares valued at about $979.65 million, a 0.3% increase.
DexCom, Inc. Stock Down 23.4%
On Tuesday, DexCom's shares traded near $69.07. The company has a market cap of $26.65 billion and a P/E ratio of 29.6, with a forward P/E of 22.4. The stock has experienced a 52-week low of $54.11 and a high of $89.98. Its 50-day moving average stands at $66.60, while the 200-day moving average is $67.52. DexCom's current ratio is 1.95, and its quick ratio is 1.58, with a debt-to-equity ratio of 46.83.
$DXCM price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
DexCom reported revenue of approximately $4.82 billion, reflecting a growth rate of 15%. The company's net margin is 19.3%, and its return on equity is 35.6%. DexCom's earnings per share (EPS) is 2.33. The next earnings report is scheduled for July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 target cuts vs 0 raises.
-
EPS & revenue
EPS beat estimates by 17.0%. Revenue missed estimates by 0.5%.
-
Profit surprise
EBITDA beat by 5 percent. Operating income beat by 21 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
4 target cuts.
-
Earnings quality
Gross margin up 6.1 points. Operating margin up 8.5 points. Positive free cash flow.
Earnings Call Summary
DexCom delivered first-quarter revenue of $1.19 billion, up fifteen percent year over year, with strong international growth of twenty-six percent. The company achieved record global new patient starts and grew U.S. market share significantly in the type 2 non-insulin segment, driven by the G7 15-day launch and better product algorithms. Management highlighted upcoming announcements including randomized control trial results at the ADA conference and new basal insulin features designed to simplify diabetes treatment.
Guidance DexCom reaffirmed full-year revenue guidance of about $5.18 billion, representing growth of eleven to thirteen percent. The company raised full-year operating profit and EBITDA margin guidance, citing strong cost control and manufacturing improvements. Management expects continued momentum from the G7 15-day product launch and potential coverage expansion for type 2 non-insulin patients later in the year.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Insider Buying and Selling at DexCom, Inc.
Recent insider transactions at DexCom include several planned sales by executives. On June 15, 2026, EVP Chief Legal Compliance Officer Michael Jon Brown sold 1,700 shares at an average price of $75.55. On the same day, Mark Foletta sold 4,000 shares at $74.14. Earlier in June, EVP Chief Commercial Officer Jon Coleman sold 4,911 shares on June 4 and 4,912 shares on June 3, with average prices of $74.13 and $73, respectively. In contrast, on May 28, 2026, Bridgette Heller and Albert Frederick Osterloh IV made open market purchases of 5,575 and 1,630 shares, respectively.
Analysts Set New Price Targets
On June 23, 2026, Deutsche Bank initiated coverage of DexCom with a buy rating and a target price of $86. Other analysts have also maintained their buy ratings recently. Piper Sandler set a target of $88 on June 15, while TD Cowen maintained a target of $95 on June 10. Mizuho reiterated a target of $85 on June 9, and Stifel set a target of $90 on June 5. Overall, the consensus among 24 analysts is a strong buy, with a mean target price of $85.21.
About DexCom, Inc.
DexCom, Inc. is a healthcare company based in San Diego, California, that specializes in medical devices. It focuses on continuous glucose monitoring systems, which are used for managing diabetes and metabolic health. The company offers products like the Dexcom G7 and G6 systems, and markets them to healthcare professionals. DexCom was founded in 1999 and is led by CEO Jacob Steven Leach, employing around 11,000 people globally.
Bottom Line
DexCom, Inc. remains a closely watched company in the medical devices sector, particularly for its innovative glucose monitoring systems. Deutsche Bank's reiteration of a buy rating with a target price of $86 reflects confidence in the company's growth prospects. As always, investors should remember that analyst ratings are based on past performance and projections that may not always come to fruition.
Get DexCom, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DXCM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.